NCT06433219 2026-02-18
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono
Phase 2 Active not recruiting
EMD Serono
Actuate Therapeutics Inc.
Aadi Bioscience, Inc.
Massachusetts General Hospital